Visicoil


Safety, Efficiency and Clinical Confidence in Tumor Targeting

    Patient Safety
  • Non-migrating design
  • Visualizing tissue deformation and motion

    Treatment Efficiency
  • Faster patient set up based on unambiguous marker geometry
  • One marker – two reference points

    Clinical Confidence
  • Accurate tumor targeting at planning and treatment due to minimized artifacts

Clinical Application Series

    Prostate
  • 2 x 1 cm VISICOIL markers placed on each side of the urethra in the left and right lobe of the prostate. All 4 marker end points used for tumor targeting
  • Alternative application: 3 x 0.5 cm VISICOIL markers placed in the base, mid-gland and apex triangulation

    Lung
  • Percutaneous implantation: Typically up to 3 VISICOIL markers (1 placed in the lesion, 2 optionally outside the lesion)
  • Superdimension bronchoscopy approach: Usually 4 or 5 VISICOIL markers implanted in and around the tumor

    Liver
  • Typically 1 VISICOIL marker inside the tumor, one optional marker outside the tumor

    Breast
  • Physician's offi ce: Generally 2 or 3 VISICOIL markers implanted under ultrasound for guidance during IGRT
  • Breast surgeon: 4 VISICOIL markers typically implanted at the end of a lumpectomy in a hospital, also to aid in IGRT and follow up

    Pancreas
  • Generally 2 x 0.5 mm VISICOIL markers implanted via endoscopic ultrasound (EUS)

    Esophagus / Bladder
  • Typically 2 VISICOIL markers implanted in and or around the lesion

    Cervix
  • Generally 2 VISICOIL markers implanted

    Fossa Bed Prostate
  • Generally 3 VISICOIL markers implanted

    Tongue, Tonsil
  • Typically 1 VISICOIL marker implanted

Visicoil
Visicoil
Visicoil